EN PT


0078/2017 - Challenges of a product development partnership: the case of a malaria treatment
Desafios de uma parceria para o desenvolvimento de produtos: o caso de um tratamento para malária

Author:

• Vera Lucia Luiza - Lucia Luiza, Vera - Rio de Janeiro - Escola Nacional de Saude Publica, Departamento de Política de Medicamentos e Assistência Farmacêutica - <vera@ensp.fiocruz.br> +
ORCID: https://orcid.org/0000-0001-6245-7522

Co-author(s):

• Gabriela Costa Chaves - Chaves, G. C. - Fundação Oswaldo Cruz, Política de Medicamentos e Assistência Farmacêutica - <gabicostachaves@gmail.com>
ORCID: https://orcid.org/0000-0002-8347-6164
• Eric Stobbaerts - Stobbaerts, Eric - Drugs for Neglected Diseases initiative - <estobbaerts@dndi.org>
• Luciana de Paula Barros Goncalves - Goncalves, Luciana de Paula Barros - Medicamentos para Doenças Negligenciadas - DNDi AL, Consultoria - <lucianapbg@yahoo.com>
• Tayná Marques Torres Barboza - Barboza, Tayná Marques Torres - Escola Nacional de Saude Publica - <taynamtb@gmail.com>

Thematic Area:

Não Categorizado

Abstract:

This paper aims to analyze the development process of the artesunate and mefloquine in fixed dose combination (ASMQ-FDC) in Brazil in the light of access to medicines dimensions so as to record the learning and the successes and problems. This was a case study of the development of an anti-malarial drug within a public-private partnership. Semi-structured interviews were conducted with key actors involved in the different stages of ASMQ-FDC development. In addition, documents provided by respondents were analyzed. A framework of access to medicines as well as program evaluation were important references that oriented the study design and data analysis. Despite the many successes landmarks throughout the project, the adoption planning of the product was insufficiently adderessed in architecture, irregularities in demand led to difficulties in the production planning and the product had irregular adoption in the region of the Americas. The project can be considered successful, having achieved the product and met the proposed pillars of capacity building and alliances both institutional and individual, and advocacy. However, it was possible to record process weaknesses to be mitigated in future projects of the same nature.

Keywords:

Orphan Drug Production Access to medicine Malaria Neglected diseases

Content:

Access Issue in Scielo

Other languages:







How to

Cite

Lucia Luiza, Vera, Chaves, G. C., Stobbaerts, Eric, Goncalves, Luciana de Paula Barros, Barboza, Tayná Marques Torres. Challenges of a product development partnership: the case of a malaria treatment. Cien Saude Colet [periódico na internet] (2017/Feb). [Citado em 22/01/2025]. Está disponível em: http://cienciaesaudecoletiva.com.br/en/articles/challenges-of-a-product-development-partnership-the-case-of-a-malaria-treatment/16124?id=16124&id=16124



Execution



Sponsors